Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Acquir Immune Defic Syndr ; 55(1): 82-6, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20395869

ABSTRACT

BACKGROUND: To evaluate the potential drug-drug interaction between raltegravir and pravastatin. METHODS: This was an open-label, randomized, 3-period, cross-over, single-centre trial in 24 healthy volunteers. Subjects received the following treatments: pravastatin 40 mg every day for 4 days, raltegravir 400 mg twice a day for 4 days, and pravastatin 40 mg every day + raltegravir 400 mg twice a day for 4 days. The treatments were separated by washout periods of 10 days. On day 4 of each treatment period, blood samples for pharmacokinetics were collected throughout a 24-hour period. RESULTS: Geometric mean ratios (90% confidence interval) for pravastatin + raltegravir versus pravastatin alone were 0.96 (0.83 to 1.11) for AUC0-24 and 1.04 (0.85 to 1.26) for Cmax. The mean low-density lipoprotein cholesterol decrease after 4 days of pravastatin was 0.42 mmol/L both in the presence and the absence of raltegravir. The geometric mean ratio (90% confidence interval) AUC0-12, Cmax, and C12 for raltegravir + pravastatin versus raltegravir alone were 1.13 (0.77 to 1.65), 1.31 (0.81 to 2.13), and 0.59 (0.39 to 0.88), respectively. CONCLUSIONS: Raltegravir did not influence the pharmacokinetics or the short-term lipid-lowering effects of pravastatin, whereas pravastatin increased the Cmax but decreased the C12 of raltegravir. The effects of pravastatin on raltegravir pharmacokinetics are not likely to be clinically relevant.


Subject(s)
Anti-Retroviral Agents/pharmacokinetics , Anticholesteremic Agents/pharmacokinetics , Pravastatin/pharmacokinetics , Pyrrolidinones/pharmacokinetics , Adult , Anti-Retroviral Agents/administration & dosage , Anticholesteremic Agents/administration & dosage , Blood Chemical Analysis , Cross-Over Studies , Drug Interactions , Female , Healthy Volunteers , Humans , Male , Middle Aged , Pravastatin/administration & dosage , Pyrrolidinones/administration & dosage , Raltegravir Potassium , Young Adult
2.
J Clin Pharmacol ; 49(10): 1220-7, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19717722

ABSTRACT

The authors studied the effect of raltegravir on the pharmacokinetics of the antiepileptic agent lamotrigine. Twelve healthy volunteers (group A) received 400 mg raltegravir twice daily from days 1 to 5. On day 4, a single dose of 100 mg lamotrigine was administered. After a washout period, participants received a second single dose of 100 mg of lamotrigine but now without raltegravir (day 32). In group B, 12 participants received the same treatment as in group A but in reverse order. On days 4 and 32, 48-hour pharmacokinetic curves were drawn. Geometric mean ratios (+90% confidence intervals [CIs]) of lamotrigine area under the plasma concentration-time curve (AUC(0-->48)) and peak plasma concentration (C(max)) for raltegravir + lamotrigine versus lamotrigine alone were 0.99 (0.96-1.01) and 0.94 (0.89-0.99), respectively. The mean ratio of the AUC(0-->48) of lamotrigine-2N-glucuronide to lamotrigine was similar when lamotrigine was taken alone (0.35) or when taken with raltegravir (0.36). Raltegravir does not influence the glucuronidation of lamotrigine.


Subject(s)
Anticonvulsants/pharmacokinetics , Glucuronosyltransferase/antagonists & inhibitors , HIV Integrase Inhibitors/pharmacokinetics , Pyrrolidinones/pharmacokinetics , Triazines/pharmacokinetics , Adult , Anticonvulsants/administration & dosage , Drug Administration Schedule , Drug Interactions , HIV Integrase Inhibitors/administration & dosage , HIV Integrase Inhibitors/adverse effects , Humans , Lamotrigine , Male , Medication Adherence , Middle Aged , Pyrrolidinones/administration & dosage , Pyrrolidinones/adverse effects , Raltegravir Potassium , Triazines/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...